SAN RAFAEL, Calif. (AP) _ BioMarin Pharmaceutical Inc. (BMRN) on Wednesday reported a third-quarter loss of $36.5 million, after reporting a profit in the same period a year earlier.

The San Rafael, California-based company said it had a loss of 20 cents per share. Earnings, adjusted for stock option expense and non-recurring costs, were 18 cents per share.

The results surpassed Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for earnings of 11 cents per share.

The rare disease biopharmaceutical posted revenue of $408.7 million in the period, which missed Street forecasts. Nine analysts surveyed by Zacks expected $431.9 million.

BioMarin expects full-year revenue in the range of $1.82 billion to $1.88 billion.

BioMarin shares have fallen 18% since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $71.72, a decrease of nearly 6% in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BMRN at https://www.zacks.com/ap/BMRN

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News